XOMA Royalty (XOMA) Non-Current Deffered Revenue (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Non-Current Deffered Revenue came in at $2.9 million in Q1 2026, down 29.97% year-on-year from $4.1 million in Q1 2025, and down 10.43% quarter-over-quarter from $3.2 million in Q4 2025.
XOMA Royalty (XOMA) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Non-Current Deffered Revenue across 17 years of filings, most recently posting $2.9 million for Q1 2026.
- Non-Current Deffered Revenue for Q1 2026 came in at $2.9 million, down 29.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (down 29.97% YoY), and the FY2025 annual result was $3.2 million, down 27.6% from the prior year.
- Non-Current Deffered Revenue came in at $2.9 million for Q1 2026 at XOMA Royalty, down from $3.2 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $11.3 million in Q1 2022 to a low of $2.9 million in Q1 2026.
- The 5-year median for Non-Current Deffered Revenue is $6.7 million (2024), against an average of $6.7 million.
- Across the five-year window, Non-Current Deffered Revenue declined 13.59% in 2022 and sank 38.99% in 2024, its largest moves.
- XOMA Royalty's Non-Current Deffered Revenue stood at $9.5 million in 2022, then slipped by 24.31% to $7.2 million in 2023, then tumbled by 38.99% to $4.4 million in 2024, then slipped by 27.6% to $3.2 million in 2025, then slipped by 10.43% to $2.9 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $2.9 million (Q1 2026), $3.2 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 2.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.86 Mn |
| Dec 31, 2025 | 3.19 Mn |
| Sep 30, 2025 | 3.47 Mn |
| Jun 30, 2025 | 3.67 Mn |
| Mar 31, 2025 | 4.08 Mn |
| Dec 31, 2024 | 4.41 Mn |
| Sep 30, 2024 | 5.59 Mn |
| Jun 30, 2024 | 5.96 Mn |
| Mar 31, 2024 | 6.69 Mn |
| Dec 31, 2023 | 7.23 Mn |
| Sep 30, 2023 | 7.80 Mn |
| Jun 30, 2023 | 8.45 Mn |
| Mar 31, 2023 | 9.04 Mn |
| Dec 31, 2022 | 9.55 Mn |
| Sep 30, 2022 | 10.38 Mn |
| Jun 30, 2022 | 10.84 Mn |
| Mar 31, 2022 | 11.35 Mn |
| Dec 31, 2021 | 11.69 Mn |
| Sep 30, 2021 | 12.31 Mn |
| Jun 30, 2021 | 12.73 Mn |